• Type II DM:
    • 5mg OD AM
    • Can be increased to 10mg
  • Heart failure (Class II-IV) with reduced ejection fraction:
    • 10mg OD
  • Risk reduction of sustained eGFR decline, ESRD, cardiovascular death and heart failure hospitalization:
    • 10mg OD
  • Tablet:
    • 5mg
    • 10mg
  • To be administered in the morning without regards to meals

Selective sodium-glucose transporter-2 (SGLT2) inhibitor

It inhibits SGLT2 reducing glucose/sodium reabsorption, increasing urinary glucose excretion and sodium delivery to distal tubule

  • Genital mycotic infection
  • Nasopharyngitis
  • UTI
  • Back pain
  • Increased urination
  • Nausea
  • Influenza
  • Constipation
  • Urinary discomfort
  • Extremity pain
  • Increased creatine
  • Orthostatic hypotension
  • Hypersensitivity to class/components
  • Pregnancy 2nd or 3rd trimester
  • Type I DM
  • Diabetic ketoacidosis
  • Volume depletion
  • Dialysis

None restricted

                          Drug Status

Availability Prescription only
Pregnancy Category C
Breastfeeding Contraindicated
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Dapaflo 10mg Tablet 30’s Dawa Ltd Dawa Ltd
Dapaflo 5mg Tablet 30’s Dawa Ltd Dawa Ltd
Dapaveldactin 5mg Tablet 28’s Liptis Pharma Goodman Agencies
Dapaveldactin 10mg Tablet 28’s Liptis Pharma Goodman Agencies
Dapawin 5mg Tablet 14’s Beacon Medicare Generics Africa
Dapazin 5mg Tablet 14’s Innocia Lifesciences Wessex Pharma
Dapazin 10mg Tablet 14’s Innocia Lifesciences Wessex Pharma
Dapiga 5mg Tablet 30’s Zawadi Healthcare Zawadi Healthcare
Dapiga 10mg Tablet 30’s Zawadi Healthcare Zawadi Healthcare
Forxiga 10mg Tablet 28’s AstraZeneca AstraZeneca
Forxiga 10mg Tablet 28’s Astrazeneca Astrazeneca
Forxiga 5mg Tablet 28’s Astrazeneca Astrazeneca
Glysit 5mg Tablet 28’s Cosmos Ltd Cosmos Ltd
Glysit 10mg Tablet 28’s Cosmos Ltd Cosmos Ltd